Signal transducer and activator of transcription 3 inhibitors: a patent review
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Aberrant activation of signal transducer and activator of transcription (Stat) 3, a member of the STAT family of proteins, is prevalent in numerous human cancers and is now widely recognized as a critical molecular abnormality and a master regulator of tumor processes. Thus, the identification of potent and selective Stat3 inhibitors will have a high commercial potential as anticancer drugs, given the many tumors in which Stat3 is implicated. AREAS COVERED IN THIS REVIEW: This review covers the structures and activities of direct inhibitors of Stat3 protein activity described in the patent literature since the research field's inception in 2001. The patents reviewed include peptide and peptidomimetic compounds, small molecules, oligonucleotides and platinum-based Stat3 inhibitors. WHAT THE READER WILL GAIN: Readers will gain an understanding of how Stat3 protein function has been inhibited by a wide variety of structurally diverse therapeutic compounds. Readers will learn about which classes of patented Stat3 inhibitors are most advanced toward clinical trials, and will be exposed to the proposed mechanisms of inhibition and scope of their application in treating human cancers. TAKE HOME MESSAGE: Numerous groups have shown that in vivo administration of inhibitors of activated Stat3 induce human tumor regression in xenograft models. Indeed, the growing number of preclinical studies in numerous cancer types, as well as the first Phase 0 clinical trial of a Stat3 inhibitor, suggest that Stat3 is a valid and exciting therapeutic target for molecular inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“Unactivated Stat3 protein (either monomeric [6,9] or dimeric [10-12]) is then recruited to phosphorylated sites on the receptor via its phosphotyrosine (pY)-binding Src Homology 2 (SH2) domain.”
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
A family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · cited 3×
“Normally, Stat3 activity is transient, responding to specific extracellular cytokine and growth factor receptor stimulation [3-6], and relaying the signal to the nucleus and promoting the expression of Stat3-specific gene profiles.”
Transcription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194 · cited 1×
“In normal cells, STAT activity is transiently activated and inhibited by a number of deactivation mechanisms, including SOCS proteinmediated silencing [13,14], association with protein inhibitors of activated STATs [15], dephosphorylation by nuclear phosphatases [14,16-18] and proteasomal degradation [19,20].”
Specific Inhibition of Stat3 Signal Transduction by PIAS3
Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., & Shuai, K. (1997) · Science · doi:10.1126/science.278.5344.1803 · Cited by 980 · cited 1×
“In normal cells, STAT activity is transiently activated and inhibited by a number of deactivation mechanisms, including SOCS proteinmediated silencing [13,14], association with protein inhibitors of activated STATs [15], dephosphorylation by nuclear phosphatases [14,16-18] and proteasomal degradation [19,20].”
Stahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., & Yancopoulos, G. D. (1995) · Science · doi:10.1126/science.7871433 · Cited by 979 · cited 1×
“evaluated several phosphopeptide sequences containing the pTyr-Xxx-Xxx-Gln consensus sequence, a common Stat3 SH2 domain-binding motif [33,41-43].”
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells
Sherry, M. M., Reeves, A., Wu, J. K., & Cochran, B. H. (2009) · Stem Cells · doi:10.1002/stem.185 · Cited by 478
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
Leong, P. L., Andrews, G. A., Johnson, D. E., Dyer, K. F., Xi, S., Mai, J. C., Robbins, P. D., Gadiparthi, S., Burke, N. A., Watkins, S. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0534764100 · Cited by 340
Haspel, R. L., Salditt‐Georgieff, M., & Darnell, J. E. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01016.x · Cited by 312 · cited 1×
“In normal cells, STAT activity is transiently activated and inhibited by a number of deactivation mechanisms, including SOCS proteinmediated silencing [13,14], association with protein inhibitors of activated STATs [15], dephosphorylation by nuclear phosphatases [14,16-18] and proteasomal degradation [19,20].”
Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188
Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., & Turkson, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.001 · Cited by 179
Self-citationZhang, T., Kee, W. H., Seow, K. T., Fung, W., & Cao, X. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.19.7132-7139.2000 · Cited by 150
Identification of a High-Affinity Phosphopeptide Inhibitor of Stat3
Ren, Z., Cabell, L. A., Schaefer, T. S., & McMurray, J. S. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)01050-8 · Cited by 128 · cited 6×
“[33,40], from the MD Anderson Cancer Center, patented more potent Stat3 SH2 domain binding hexapeptides (US/2007/0010428), Ac-pTyr-Leu-Lys-Thr-Lys-Phe and Ac-pTyr-Leu-Pro-GlnThr-Val-NH2 (2 and 3, Figure 2), via screening phosphopeptide sequences derived from proteins known to interact with Stat3 (such as Stat3, gp130,…”
InfluentialA Novel Sequence in the Coiled-coil Domain of Stat3 Essential for Its Nuclear Translocation
Ma, J., Zhang, T., Novotny-Diermayr, V., Tan, A. L. C., & Cao, X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304196200 · Cited by 110
Cited by
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Bonetto, A., Aydogdu, T., Jin, X., Zhang, Z., Zhan, R., Puzis, L., Koniaris, L. G., & Zimmers, T. A. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00039.2012 · Cited by 463
Interleukin-6: from an inflammatory marker to a target for inflammatory diseases
Rincon, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.003 · Cited by 328
Subramaniam, A., Shanmugam, M. K., Perumal, E., Li, F., Nachiyappan, A., Dai, X., Swamy, S. N., Ahn, K. S., Kumar, A. P., Tan, B. K. H., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.002 · Cited by 278
Metadata
- Authors
- Page, B. D., Ball, D. P., & Gunning, P. T.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2010-11-29
- Volume
- 21
- Issue
- 1
- Pages
- 65-83
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2069045375
- Cited by
- 102
- References
- 17
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.